News

News 29.10.2018 Zurich-Schlieren, October 29, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in...

News 24.10.2018 Schlieren (Zurich), Switzerland, October 22, 2018 – Kuros Biosciences AG (SIX: KURN) announced that its Dutch subsidiary, Kuros Biosciences BV, has recently been granted the US patent, US 10’064’892, entitled “Method for producing an osteoinductive calcium phosphate and products thus obtained” by the United States Patent and Trademark Office (USPTO). The patent covers...

News 05.09.2018 Financial highlights CHF 9.7 million cash at June 30 Operating expenses decreased to CHF 6.0 million Operational highlights First U.S. & European sales of MagnetOs Commercial rollout in the U.S. and Europe on track Preparation for Phase II clinical study of Fibrin-PTH in spine on track Download report

News 30.08.2018 Promising initial data from MP0250 combination with bortezomib (Velcade®) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer supported by...

News 27.08.2018 ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors. Altos Venture (Allschwil, Switzerland), a Swiss venture capital firm chaired by Dr....